The trial is taking place at:
N

Neuro Pain Medical Center | Fresno, CA

Veeva-enabled site

Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity

AbbVie logo

AbbVie

Status and phase

Active, not recruiting
Phase 2
Phase 1

Conditions

Upper Limb Spasticity

Treatments

Drug: Placebo for ABBV-950
Biological: ABBV-950
Biological: BOTOX

Study type

Interventional

Funder types

Industry

Identifiers

NCT05956509
M23-499

Details and patient eligibility

About

Spasticity is often observed as muscle tightness and stiffness in the upper and/or lower limbs. Upper limb spasticity can interfere with joint movement and its severity can range from mild to severe. Common causes of spasticity include cerebral palsy, traumatic brain injury, multiple sclerosis, spinal cord injury, and stroke. This study will assess how safe and effective ABBV-950 is in treating upper limb spasticity in adult post-stroke participants. Adverse events and change in symptoms will be assessed. ABBV-950 in an investigational drug being developed for treating spasticity. This study is conducted in 2 parts. In Part 1, participants are assigned to receive different doses of ABBV-950 or placebo. There is 1 in 4 chance that participants will be assigned to receive placebo. In Part 2, participants will be randomly assigned to receive BOTOX, ABBV-950, or placebo. There is 1 in 5 chance for participants to receive placebo. Approximately 297 adult post-stroke participants with upper limb spasticity will be enrolled at approximately 50 sites in the United States. In Part 1, participants will receive intramuscular (IM) injections of ABBV-950 or placebo on Day 1. In Part 2, participants will receive IM injections of BOTOX, ABBV-950, or placebo on Day 1. All participants will be followed for 24 weeks. There may be higher treatment burden for participants in this trial compared to the standard of care. Participants will attend regular clinic visits during the study. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

Enrollment

297 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

* Diagnosis of upper limb spasticity due to stroke, with most recent stroke occurring at least 12 weeks prior to the Screening visit. * Modified Ashworth Scale-Bohannon (MAS-B) score of \>= 3 in the wrist flexors, and a score of \>= 1+ in the finger flexors and MAS-B score of \>= 2 elbow flexors at both Screening and Visit 2 (Baseline).

Exclusion criteria

* Additional strokes in the 12 weeks preceding the most recent stroke and in the opinion of the investigator, is not at significant risk of experiencing another stroke during the study period. * Spasticity in the contralateral upper limb that requires treatment. * Presence of fixed contractures in muscles of wrist, elbow, fingers. * Botulinum toxin treatment of any serotype in the 20 weeks prior to Day for upper limb spasticity and in the 12 weeks prior to Day 1 for any indication other than upper limb spasticity. * Previous surgical intervention, nerve block, or muscle block for the treatment of spasticity in the study limb in the last 12 months. * Injection of corticosteroids or anesthetics in the study limb within 12 weeks. * Casting of the upper limbs within 12 weeks. * Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, and/or amyotrophic lateral sclerosis.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Sequential Assignment

Masking

Quadruple Blind

297 participants in 11 patient groups, including a placebo group

Part 1: ABBV-950 Dose A
Experimental group
Description:
Participants will receive ABBV-Dose A on Day 1.
Treatment:
Biological: ABBV-950
Part 1: Placebo for ABBV-950 Dose A
Placebo Comparator group
Description:
Participants will receive placebo for ABBV-950 on Day 1.
Treatment:
Drug: Placebo for ABBV-950
Part 1: ABBV-950 Dose B
Experimental group
Description:
Participants will receive ABBV-950 Dose B on Day 1.
Treatment:
Biological: ABBV-950
Part 1: Placebo for ABBV-950 Dose B
Placebo Comparator group
Description:
Participants will receive placebo for ABBV-950 on Day 1.
Treatment:
Drug: Placebo for ABBV-950
Part 1: ABBV-950 Dose C
Experimental group
Description:
Participants will receive ABBV-950 Dose C on Day 1.
Treatment:
Biological: ABBV-950
Part 1: Placebo for ABBV-950 Dose C
Placebo Comparator group
Description:
Participants will receive placebo for ABBV-950 on Day 1.
Treatment:
Drug: Placebo for ABBV-950
Part 2: BOTOX Dose A
Active Comparator group
Description:
Participants will receive BOTOX Dose A on Day 1.
Treatment:
Biological: BOTOX
Part 2: ABBV-950 Dose A
Experimental group
Description:
Participants will receive ABBV-950 Dose A on Day 1.
Treatment:
Biological: ABBV-950
Part 2: ABBV-950 Dose B
Experimental group
Description:
Participants will receive ABBV-950 Dose B on Day 1.
Treatment:
Biological: ABBV-950
Part 2: ABBV-950 Dose C
Experimental group
Description:
Participants will receive ABBV-950 Dose C on Day 1.
Treatment:
Biological: ABBV-950
Part 2: Placebo for ABBV-950
Placebo Comparator group
Description:
Participants will receive placebo for ABBV-950 on Day 1.
Treatment:
Drug: Placebo for ABBV-950

Trial contacts and locations

8

Loading...

Central trial contact

ABBVIE CALL CENTER

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems